Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

• Status: Not yet recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abramson Cancer Center of the University of Pennsylvania
• Collaborator: Genentech, Inc.
• Treatments: Atezolizumab

Criteria

Inclusion Criteria:

• Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older

• Prior exposure to at least 1 line of therapy

• Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial

• ECOG PS 0-2

Exclusion Criteria:

• Presence of a driver mutation that is susceptible to targeted therapy

• No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy

• Other active invasive malignancy requiring ongoing therapy

• Evidence of progressing or untreated brain metastases

• Evidence or history of leptomeningeal disease

• Uncontrolled tumor related pain

• History of an autoimmune disease or IPF